We are pleased to announce the 3rd edition of the Molecular Analysis for Personalised therapy (MAP) meeting, to be held in Zurich, October 13-14 2017.
A joint initiative of Cancer Research UK, UNICANCER and ESMO, this conference will explore clinical interpretation of molecular tests for metastatic cancers.
The development of new biotechnologies has revolutionised the applications of personalised therapy in metastatic cancer. It is now possible to perform multigene sequencing for cancer patients, either in clinical trials, or in routine use.
Unfortunately, while the technologies are robust, the interpretations of these molecular analyses is still a matter of debate, and there is a need to understand which molecular alterations should be targeted in cancer patients.
We recently outlined the need for such a conference in Annals of Oncology:
"Regular consensus meeting and transparency of data reporting (both positive and negative) will likely form a vital component of research community efforts to share experience and inform the next generation of clinical trials… These efforts should optimally be done under the sponsorship of an international scientific society."
The MAP conference will equip clinicians and researchers to interpret clearly the molecular analyses of their patients.
Scientific presentations by international leaders will highlight the latest advances in the field of personalised medicine for cancer patients.
Genomic clinical cases will offer some real-life examples of clinical interpretation in this field of genetic science.
Roundtable discussions will allow participants to exchange on how to prioritise targets in cancer patients.
We hope to see you at this exciting conference, where we discuss this emerging topic in detail and offer oncologists practical solutions for clinical treatment.
MAP Founders and Scientific Board